Stock listing

NASDAQ:MRKR Marker Therapeutics, Inc. Stock

Home listing (NASDAQ) of Marker Therapeutics, Inc.

Follow Marker Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:MRKR

$1.09 USD -0.23 (-17.4%)

Close on Nov 20, 2026

Past year +10.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.09 – $1.45 USDNov 20, 2026
Volume
1.88M sharesNov 20, 2026
Market cap
$18.17M USDAt the close on Nov 20, 2026 · price × 16.67M shares outstanding
52-week range
$0.81 – $2.46 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$879,874 USDMedian day 91,050 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Marker Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:MRKR · Home$1.09 USD-0.23 (-17.4%)1,877,767$1.34$1.45$1.09$1.32Close on Nov 20, 2026
Frankfurt:GX1€0.969 EUR-0.330 (-25.4%)—€1.054€1.177€0.966€1.299Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MRKR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.09-0.23-17.4%$1.34$1.45$1.091,877,767
$1.32+0.467+54.7%$1.02$1.68$0.98436,085,341
$0.853+0.017+2.0%$0.844$0.92$0.835105,843
$0.837+0.008+1.0%$0.871$0.903$0.81203,542
$0.829-0.041-4.8%$0.898$0.912$0.82135,857
$0.87-0.03-3.3%$0.92$0.93$0.8776,100
$0.90-0.05-5.3%$0.95$0.97$0.90140,800
$0.950.000.0%$0.95$0.98$0.9428,400
$0.95-0.04-4.0%$1.01$1.03$0.9553,000
$0.99+0.10+11.2%$0.93$1.05$0.87231,400
$0.89-0.01-1.1%$0.90$0.95$0.8950,400
$0.90-0.11-10.9%$1.00$1.03$0.88189,000
$1.01+0.03+3.1%$0.99$1.05$0.9993,400
$0.98+0.08+8.9%$0.91$1.00$0.8994,600
$0.90-0.08-8.2%$0.96$0.97$0.88265,700
$0.98-0.03-3.0%$1.03$1.04$0.9667,600
$1.01+0.01+1.0%$0.99$1.07$0.9872,900
$1.00+0.05+5.3%$0.96$1.07$0.9086,900
$0.95+0.04+4.4%$0.92$0.98$0.89103,900
$0.91-0.05-5.2%$0.95$1.04$0.87217,600
$0.96-0.11-10.3%$1.07$1.12$0.96114,400
$1.07-0.06-5.3%$1.17$1.17$1.0791,500
$1.13-0.03-2.6%$1.16$1.27$1.13149,900
$1.16-0.04-3.3%$1.19$1.24$1.11209,400
$1.20+0.16+15.4%$1.09$1.20$1.05578,800
$1.04+0.12+13.0%$1.02$1.20$1.001,146,100
$0.92+0.03+3.4%$0.96$0.96$0.88120,200
$0.89-0.03-3.3%$0.92$0.95$0.8965,800
$0.92-0.09-8.9%$1.03$1.03$0.91175,200
$1.01+0.04+4.1%$0.98$1.03$0.98107,800
$0.97+0.02+2.1%$0.93$1.00$0.9391,200
$0.95-0.09-8.7%$1.04$1.05$0.9596,900
$1.04+0.03+3.0%$1.03$1.06$1.0337,500
$1.01-0.05-4.7%$1.07$1.07$1.0077,100
$1.06+0.01+1.0%$1.08$1.09$1.0573,500
$1.050.000.0%$1.06$1.08$1.02100,300
$1.05-0.02-1.9%$1.08$1.09$0.98127,500
$1.07-0.03-2.7%$1.12$1.14$1.0738,400
$1.10-0.03-2.7%$1.14$1.16$1.0890,900
$1.13-0.02-1.7%$1.12$1.15$1.07164,300
$1.15-0.04-3.4%$1.22$1.22$1.1529,600
$1.19-0.05-4.0%$1.26$1.31$1.15141,600
$1.24+0.02+1.6%$1.24$1.27$1.2364,900
$1.22+0.02+1.7%$1.18$1.24$1.1838,700
$1.20+0.02+1.7%$1.18$1.22$1.1824,200
$1.180.000.0%$1.19$1.23$1.1747,300
$1.18+0.04+3.5%$1.13$1.23$1.1360,600
$1.14-0.03-2.6%$1.17$1.18$1.1335,900
$1.170.000.0%$1.17$1.23$1.1512,000
$1.17+0.02+1.7%$1.16$1.23$1.1617,400
$1.15-0.05-4.2%$1.20$1.25$1.1059,400
$1.20-0.01-0.8%$1.21$1.23$1.1855,500
$1.21-0.07-5.5%$1.29$1.29$1.2171,200
$1.28+0.10+8.5%$1.19$1.39$1.19200,300
$1.18-0.06-4.8%$1.25$1.31$1.1835,300
$1.24-0.01-0.8%$1.24$1.31$1.2243,400
$1.25-0.05-3.8%$1.25$1.33$1.24167,600
$1.30-0.03-2.3%$1.31$1.34$1.2621,000
$1.33-0.04-2.9%$1.37$1.41$1.3159,500
$1.37-0.09-6.2%$1.50$1.50$1.3584,800
$1.46+0.01+0.7%$1.45$1.50$1.4024,500
$1.45-0.07-4.6%$1.52$1.59$1.4533,800
$1.52+0.02+1.3%$1.50$1.60$1.48146,700
$1.50+0.11+7.9%$1.44$1.53$1.41238,000
$1.39+0.17+13.9%$1.25$1.44$1.2599,400
$1.22-0.07-5.4%$1.28$1.32$1.1980,600

Splits

5 splits since 2007 · NASDAQ:MRKR · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
1-for-12Consolidation
1-for-100Consolidation
1-for-10Consolidation
2-for-5Consolidation
Ticker
NASDAQ:MRKR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Marker Therapeutics, Inc. news

Marker Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
6 in the last 12 months · 106 in all · newest Nov 19, 2026 · oldest 2019
Calls
1 call with a replay · 1 with a transcript · latest Feb 16, 2022
Decks
14 decks · latest November 2025

Where Marker Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:MRKR · Home listing · This pageNASDAQUnited StatesUSD
gettex:GX1gettexGermanyEUR
BOATS:MRKRBOATSUnited StatesUSD
Frankfurt:GX1FrankfurtGermanyEUR
Munich:GX1MunichGermanyEUR

Valuation

EV/sales 4.9× against a median of 15.6×: 2nd lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$9.13M USD
P/E
Loss
EV/sales
4.9×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
1.7×
Gross margin
Not reported
Operating margin
−504.7%
Net margin
−461.1%
Debt to equity
0.0×
Beta vs S&P 500
1.49

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Marker Therapeutics, Inc. · NASDAQ:MRKRUS$18.17MUS$9.13Mn/a4.9×n/a1.7×−461.1%0.0×1.49
Adicet Bio, Inc. · NASDAQ:ACETUS$20.03MUS$5.02Mn/an/an/a0.2×n/a0.1×2.02
IGC Pharma, Inc. · AMEX:IGCUS$19.60MUS$19.19Mn/an/an/a3.0×n/a0.0×1.09
Provectus Biopharmaceuticals, Inc. · OTC:PVCTUS$19.12MUS$18.94Mn/an/an/an/an/an/a-0.21
LeonaBio, Inc. · NASDAQ:LONAUS$19.03M−US$12.82Mn/an/an/a1.2×n/a0.0×1.04
Cocrystal Pharma, Inc. · NASDAQ:COCPUS$18.30MUS$14.69Mn/a33.8×n/a6.8×n/a0.5×1.21
Syntara Limited · ASX:SNTUS$18.20MUS$9.23Mn/a2.0×n/a1.7×−129.8%0.0×n/a
Resverlogix Corp. · TSX:RVXUS$18.01MUS$95.55Mn/an/an/an/an/an/a0.26
SynCore Biotechnology Co., Ltd. · TPEX:4192US$16.80MUS$12.38Mn/a15.6×n/a2.5×−178.5%0.0×n/a
Initiator Pharma A/S · OMXSTO:INITUS$16.76MUS$15.67Mn/an/an/a13.4×n/a1.1×n/a
Neurotech International Ltd. · ASX:NTIUS$16.63MUS$15.06Mn/an/an/a41.1×n/a0.0×n/a
Median of the othersUS$18.25MUS$14.87M15.6×2.8×−154.2%0.0×1.07

Forecasts

3 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
7.87 USD · Analysts' mean
EPS, year to Dec 2026
-0.56 · 2 analysts
Revenue, year to Dec 2026
4.24M · 3 analysts

Team and board

Officers

OfficerRole
Juan F. VeraChief Executive Officer & Co-Founder, Marker Therapeutics
Kathryn Penkus CorzoPresident and Chief Operating Officer, bit.bio
Edmund CheungVice President, Human Resources
Katharine KnobilChief Medical Officer, Altesa BioSciences, Inc.
Mary NewmanHead of Regulatory Affairs
Patricia AllisonHead of Clinical Operations

Board

DirectorRole
David EansorDirector
Juan F. VeraChief Executive Officer & Co-Founder, Marker Therapeutics
Katharine KnobilChief Medical Officer, Altesa BioSciences, Inc.
Kathryn Penkus CorzoPresident and Chief Operating Officer, bit.bio
Steve ElmsManaging Partner, Aisling Capital

Events

Calls

CallWhenStatus
Marker Therapeutics (NASDAQ:MRKR) Q2 2022 Earnings CallWed, Feb 16, 2022 · 5:00 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 16, 2026 · After close+1.0%
Q2 2026Aug 14, 2026 · After close+1.8%
Q1 2026May 15, 2026 · After close−2.1%
Q4 2025Mar 19, 20260.0%
Q3 2025Nov 13, 2025 · After close+3.4%
Q2 2025Aug 14, 2025 · After close+0.8%
Q1 2025May 15, 2025 · After close−1.8%
Q4 2024Mar 24, 2025 · Before open+2.4%
Q3 2024Nov 14, 2024 · After close−12.3%
Q2 2024Aug 14, 2024 · After close−5.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · After close−1.7%
Q4 2023Mar 26, 2024 · Before open−10.7%
Q3 2023Nov 9, 2023 · After close−8.4%
Q2 2023Aug 14, 2023 · After close+25.8%
Q1 2023May 15, 2023 · After close−3.6%
Q4 2022Mar 22, 2023 · Before open−31.8%
Q3 2022Nov 10, 2022 · After close0.0%
Q2 2022Aug 11, 2022 · After close−13.3%
Q1 2022May 13, 2022 · Before open+6.5%
Q4 2021Mar 17, 2022 · After close+2.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2025)Investor deck20 slidesNovember 2025
Investor Presentation (August 2025)Investor deck28 slidesAug 26, 2025
Investor Presentation (August 2025)Investor deck20 slidesAug 26, 2025
Investor Presentation (January 2024)Investor deck21 slidesJan 8, 2024
Investor Presentation (March 2021)Investor deck38 slidesMar 16, 2021
Technical Presentation (June 2020)Technical40 slidesJun 1, 2020
Investor Presentation (September 2019)Investor deck19 slidesSep 24, 2019
Technical Presentation (July 2019)Technical32 slidesJul 22, 2019
Investor Presentation (April 2019)Investor deck58 slidesApril 2019
Technical Presentation (February 2019)Technical17 slidesFeb 25, 2019
All 14 decks
DeckKindSlidesDate
Technical Presentation (February 2019)Technical26 slidesFeb 25, 2019
Technical Presentation (February 2019)Technical22 slidesFeb 25, 2019
Technical Presentation (2019)Technical66 slides2019
Technical Presentation (December 2018)Technical41 slidesDec 4, 2018

Open Decks

Financings

RaiseDate
At-the-market programme of common stock
Tranche closed: US$10M raised
Use of proceeds: Extending the company's cash runway well into 2026
Nov 14, 2025
Private placement of common stock (or pre-funded warrants) and accompanying warrants
Announced: US$16.1M · US$3.2 a share · Warrants at US$4.03 for 60 months · Canaccord Genuity +1
Dealers: Canaccord Genuity (lead), Brookline Capital Markets, a division of Arcadia Securities, LLC
Buyers: Blue Owl Healthcare Opportunities; New Enterprise Associates (NEA); Aisling Capital
Use of proceeds: Support clinical advancement of the Phase 1 APOLLO study of MT-601 in lymphoma, among other uses
Dec 19, 2024

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue3.55M6.59M3.31M3.51M0500.0K213.2K206.0K183.1K0
Cost of revenue13.5M10.4M12.0M3.16M18.9M12.8M124.0M5.25M0
Gross profit-6.88M-7.11M-8.45M-1.92M-18.4M-12.6M-123.8M-5.07M0
Research and development11.8M13.5M10.4M12.0M27.8M18.9M12.8M7.95M5.25M3.80M
Selling, general and administrative4.18M4.24M7.48M11.3M12.9M10.5M9.98M24.4M6.41M4.69M
Operating income-12.9M-11.1M-14.6M-19.8M-39.5M-28.9M-22.5M-148.2M-11.5M-8.49M
Depreciation and amortization22.79M2.79M2.15M485.6K105.1K011.5M8.49M
EBITDA-11.1M-11.8M-17.0M-37.3M-28.4M-22.4M-148.2M00
Interest expense15.1K5.70K148.7K0000
Income before tax-12.2M-10.7M-14.0M-19.8M-41.9M-28.7M-21.4M-148.0M-11.0M-2.46M
Income tax-15.2K50.0K3.67K-15.1K-5.70K-180.0K-1.10M000
Net income-12.2M-10.7M-8.24M-29.9M-41.9M-28.7M-21.4M-148.0M-11.0M-2.46M
Earnings per share, basic-0.79-1.19-0.94-3.58-5.47-0.61-0.47-7.75-1.16-0.36
Earnings per share, diluted-0.79-1.19-0.94-3.58-5.47-0.61-0.47-7.75-1.16-0.72

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents16.1M19.2M15.1M11.8M42.4M21.4M43.9M61.7M5.13M7.85M
Short-term investments19.2T
Receivables1.37M2.35M1.03M2.40M2371.00M56.2K108.2K
Inventory-988.1K-1.00M
Current assets19.1M22.0M17.1M16.6M46.0M24.4M45.5M62.0M5.18M7.92M
Property, plant and equipment12.3M12.3M10.4M418.0K147.7K0
Total assets19.1M22.0M17.1M34.4M68.1M45.6M46.4M62.1M5.18M7.92M
Accounts payable793.7K1.07M961.0K1.10M5.14M2.94M993.0K1.62M1.01M680.0K
Current liabilities2.27M3.46M3.07M7.78M12.9M6.40M1.99M2.80M1.52M1.74M
Total debt7.62M11.9M12.3M484.4K5.00K5.00K
Total liabilities2.27M3.46M3.07M14.8M24.1M18.3M2.27M2.80M1.52M1.74M
Shareholders' equity16.8M18.6M14.1M19.6M44.0M27.3M44.1M59.3M3.66M6.18M
Shares outstanding16.7M10.7M8.90M8.40M8.30M50.7M45.7M45.4M10.6M8.40M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-12.0M-10.9M-16.4M-27.0M-27.3M-20.0M-18.3M-14.5M-8.44M-6.51M
Capital spending-1-4-1-3-3.13M-9.25M-375.0K-147.7K0-147.7K
Free cash flow-12.0M-10.9M-16.4M-27.0M-30.4M-29.3M-18.7M-14.6M-8.44M-6.51M
Cash from investing18.7M-4.95M-3.13M-9.25M-375.0K-147.7K0-147.7K
Cash from financing9.86M15.0M1.11M202.1K52.6M6.74M816.5K71.2M5.72M7.78M
Share buybacks6.74M816.5K-71.7K-310.5K0
Change in cash-2.15M4.08M3.33M11.8M43.5M-22.6M-17.8M56.6M-2.72M1.27M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 19, 2026Current reportSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportOct 19, 2026Current reportSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
8-K · Current reportMay 4, 2026Meeting outcomeSEC
DEFA14A · Additional proxy materialMar 20, 2026Meeting noticeSEC
ARS · Annual report to shareholdersMar 20, 2026Annual reportSEC
DEF 14A · Proxy statementMar 20, 2026Meeting noticeSEC
8-K · Current reportMar 18, 2026ResultsSEC
Show 200 filings
FilingDateTypeFiled with
10-K · Annual reportMar 18, 2026Annual reportSEC
PRE 14A · Preliminary proxy statementMar 10, 2026Meeting noticeSEC
8-K · Current reportFeb 9, 2026Current reportSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 17, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 14, 2025ResultsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025Management or board changeSEC
4 · Change in ownershipNov 4, 2025Insider tradeSEC
4 · Change in ownershipNov 4, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 4, 2025Insider tradeSEC
8-K · Current reportOct 6, 2025Current reportSEC
8-K · Current reportAug 26, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 20, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 19, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 18, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025Current reportSEC
424B7 · ProspectusAug 5, 2025Offer documentSEC
8-K · Current reportJun 17, 2025Material contractSEC
8-K · Current reportJun 9, 2025Meeting outcomeSEC
8-K · Current reportMay 20, 2025Current reportSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 24, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2025Meeting noticeSEC
8-K · Current reportMar 31, 2025ResultsSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportMar 27, 2025Meeting outcomeSEC
8-K/A · Current report, amendedMar 4, 2025Management or board changeSEC
8-K · Current reportFeb 19, 2025Management or board changeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
DEFA14A · Additional proxy materialFeb 4, 2025Meeting noticeSEC
DEF 14A · Proxy statementFeb 4, 2025Meeting noticeSEC
8-K · Current reportJan 30, 2025Management or board changeSEC
EFFECT · Notice that a registration is effectiveJan 21, 2025Other filingsSEC
424B3 · ProspectusJan 17, 2025Offer documentSEC
CORRESP · Letter to the SECJan 15, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 15, 2025Other filingsSEC
PRE 14A · Preliminary proxy statementJan 13, 2025Meeting noticeSEC
S-3 · Registration statementJan 10, 2025Offer documentSEC
DDec 30, 2024Other filingsSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
8-K · Current reportDec 23, 2024Material contractSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 23, 2024Big-stake noticeSEC
8-K · Current reportDec 19, 2024Material contractSEC
8-K · Current reportDec 17, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveDec 9, 2024Other filingsSEC
424B3 · ProspectusDec 6, 2024Offer documentSEC
CORRESP · Letter to the SECDec 4, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 4, 2024Other filingsSEC
S-3 · Registration statementNov 27, 2024Offer documentSEC
8-K · Current reportNov 14, 2024ResultsSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportAug 14, 2024ResultsSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024Current reportSEC
8-K · Current reportJun 12, 2024Meeting outcomeSEC
SC 13D/A · Big-stake notice, amendedMay 17, 2024Big-stake noticeSEC
8-K · Current reportMay 15, 2024ResultsSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
8-K · Current reportApr 8, 2024Current reportSEC
8-K · Current reportMar 25, 2024ResultsSEC
10-K · Annual reportMar 25, 2024Annual reportSEC
8-K · Current reportMar 1, 2024Current reportSEC
8-K · Current reportFeb 26, 2024Material contractSEC
8-K · Current reportJan 8, 2024Current reportSEC
8-K · Current reportDec 11, 2023Current reportSEC
8-K · Current reportNov 20, 2023Management or board changeSEC
8-K · Current reportNov 9, 2023ResultsSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportSep 11, 2023Current reportSEC
8-K · Current reportAug 14, 2023ResultsSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportAug 7, 2023Current reportSEC
8-K · Current reportJul 10, 2023Current reportSEC
3 · Initial statement of ownershipJul 5, 2023Insider tradeSEC
8-K · Current reportJul 3, 2023Management or board changeSEC
8-K · Current reportJun 30, 2023Acquisition or disposalSEC
8-K · Current reportJun 26, 2023Current reportSEC
8-K · Current reportJun 12, 2023Current reportSEC
8-K · Current reportJun 9, 2023Meeting outcomeSEC
4 · Change in ownershipJun 8, 2023Insider tradeSEC
4 · Change in ownershipJun 8, 2023Insider tradeSEC
4 · Change in ownershipJun 8, 2023Insider tradeSEC
4 · Change in ownershipJun 8, 2023Insider tradeSEC
8-K · Current reportMay 31, 2023Current reportSEC
10-Q · Quarterly reportMay 15, 2023Quarterly reportSEC
4 · Change in ownershipMay 11, 2023Insider tradeSEC
8-K · Current reportMay 8, 2023Current reportSEC
8-K · Current reportMay 1, 2023Material contractSEC
ARS · Annual report to shareholdersApr 28, 2023Annual reportSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
424B5 · ProspectusMar 22, 2023Offer documentSEC
8-K · Current reportMar 22, 2023ResultsSEC
10-K · Annual reportMar 22, 2023Annual reportSEC
8-K · Current reportMar 16, 2023Management or board changeSEC
SC 13D/A · Big-stake notice, amendedMar 3, 2023Big-stake noticeSEC
4 · Change in ownershipMar 1, 2023Insider tradeSEC
4 · Change in ownershipMar 1, 2023Insider tradeSEC
4 · Change in ownershipMar 1, 2023Insider tradeSEC
4 · Change in ownershipMar 1, 2023Insider tradeSEC
4 · Change in ownershipMar 1, 2023Insider tradeSEC
4 · Change in ownershipMar 1, 2023Insider tradeSEC
8-K · Current reportJan 26, 2023Current reportSEC
424B3 · ProspectusJan 3, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 3, 2023Other filingsSEC
CORRESP · Letter to the SECDec 29, 2022Other filingsSEC
UPLOAD · Letter from the SECDec 29, 2022Other filingsSEC
S-1 · Registration statementDec 23, 2022Offer documentSEC
8-K · Current reportDec 13, 2022Material contractSEC
8-K · Current reportNov 22, 2022Current reportSEC
8-K · Current reportNov 10, 2022ResultsSEC
10-Q · Quarterly reportNov 10, 2022Quarterly reportSEC
8-K · Current reportOct 20, 2022Current reportSEC
8-K · Current reportSep 27, 2022Management or board changeSEC
8-K · Current reportSep 13, 2022Current reportSEC
8-K · Current reportAug 19, 2022Current reportSEC
S-8 · Registration statement for employee plansAug 11, 2022Offer documentSEC
8-K · Current reportAug 11, 2022ResultsSEC
10-Q · Quarterly reportAug 11, 2022Quarterly reportSEC
8-K · Current reportAug 4, 2022Current reportSEC
8-K · Current reportMay 27, 2022Meeting outcomeSEC
4 · Change in ownershipMay 26, 2022Insider tradeSEC
4 · Change in ownershipMay 26, 2022Insider tradeSEC
4 · Change in ownershipMay 26, 2022Insider tradeSEC
4 · Change in ownershipMay 26, 2022Insider tradeSEC
4 · Change in ownershipMay 26, 2022Insider tradeSEC
8-K · Current reportMay 13, 2022ResultsSEC
10-Q · Quarterly reportMay 12, 2022Quarterly reportSEC
8-K · Current reportApr 26, 2022Material contractSEC
DEF 14A · Proxy statementApr 15, 2022Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 6, 2022Meeting noticeSEC
8-K · Current reportApr 6, 2022Management or board changeSEC
4 · Change in ownershipMar 28, 2022Insider tradeSEC
4 · Change in ownershipMar 28, 2022Insider tradeSEC
4 · Change in ownershipMar 28, 2022Insider tradeSEC
424B5 · ProspectusMar 18, 2022Offer documentSEC
8-K · Current reportMar 17, 2022ResultsSEC
10-K · Annual reportMar 17, 2022Annual reportSEC
4 · Change in ownershipFeb 22, 2022Insider tradeSEC
4 · Change in ownershipFeb 22, 2022Insider tradeSEC
4 · Change in ownershipFeb 22, 2022Insider tradeSEC
4 · Change in ownershipFeb 22, 2022Insider tradeSEC
4 · Change in ownershipFeb 22, 2022Insider tradeSEC
4 · Change in ownershipFeb 22, 2022Insider tradeSEC
4 · Change in ownershipFeb 22, 2022Insider tradeSEC
4 · Change in ownershipFeb 22, 2022Insider tradeSEC
4 · Change in ownershipFeb 22, 2022Insider tradeSEC
8-K · Current reportFeb 18, 2022Current reportSEC
8-K · Current reportFeb 16, 2022Current reportSEC
8-K · Current reportJan 19, 2022Current reportSEC
4 · Change in ownershipDec 9, 2021Insider tradeSEC
3 · Initial statement of ownershipDec 9, 2021Insider tradeSEC
8-K · Current reportDec 9, 2021Management or board changeSEC
8-K · Current reportNov 15, 2021Management or board changeSEC
8-K · Current reportNov 10, 2021ResultsSEC
10-Q · Quarterly reportNov 10, 2021Quarterly reportSEC
EFFECT · Notice that a registration is effectiveAug 20, 2021Other filingsSEC
8-K · Current reportAug 19, 2021Current reportSEC
CORRESP · Letter to the SECAug 17, 2021Other filingsSEC
UPLOAD · Letter from the SECAug 17, 2021Other filingsSEC
S-3 · Registration statementAug 10, 2021Offer documentSEC
8-K · Current reportAug 10, 2021ResultsSEC
10-Q · Quarterly reportAug 10, 2021Quarterly reportSEC
8-K · Current reportJul 28, 2021Current reportSEC
8-K · Current reportJul 6, 2021Current reportSEC
8-K · Current reportJun 11, 2021Meeting outcomeSEC
4 · Change in ownershipJun 10, 2021Insider tradeSEC
4 · Change in ownershipJun 10, 2021Insider tradeSEC
4 · Change in ownershipJun 10, 2021Insider tradeSEC
4 · Change in ownershipJun 10, 2021Insider tradeSEC
4 · Change in ownershipJun 10, 2021Insider tradeSEC
4 · Change in ownershipMay 20, 2021Insider tradeSEC
8-K · Current reportMay 12, 2021ResultsSEC
10-Q · Quarterly reportMay 12, 2021Quarterly reportSEC
DEFR14AMay 5, 2021Meeting noticeSEC
DEFA14A · Additional proxy materialApr 23, 2021Meeting noticeSEC

This page holds 200 of 906 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Marker Therapeutics, Inc.’s releases · as of Nov 13, 2026

Common shares
16,673,127
Fully diluted
16,673,127

Fully diluted

LineSharesAs of
Common shares16,673,127Nov 13, 2026

Share count over time

CountShares
Nov 13, 202616,673,127

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
NEA Management Company, LLC1.63M9.8%US$1.74MSep 30, 2026
Blue Owl Capital Holdings LP554K3.3%US$593KSep 30, 2026
Vanguard516K3.1%US$552KSep 30, 2026
Aisling Capital Management LP325K2.0%US$348KSep 30, 2026
Renaissance Technologies267K1.6%US$286KSep 30, 2026
Geode Capital140K0.84%US$150KSep 30, 2026
Osaic Holdings, Inc.111K0.67%US$119KSep 30, 2026
Concurrent Investment Advisors, LLC67,9630.41%US$72,720Sep 30, 2026
Two Sigma66,6930.40%US$71,361Sep 30, 2026
XTX Topco Ltd36,0710.22%US$38,596Sep 30, 2026
All 33 holders
HolderSharesOf the companyValueAs of
Northern Trust34,6290.21%US$37,053Sep 30, 2026
Squarepoint Ops LLC34,4850.21%US$36,899Sep 30, 2026
Susquehanna23,0540.14%US$24,668Sep 30, 2026
State Street20,9480.13%US$22,414Sep 30, 2026
Creative Planning17,3120.10%US$18,524Sep 30, 2026
Ashton Thomas Private Wealth, LLC16,4000.10%US$17,548Sep 30, 2026
Jane Street12,2500.07%US$13,108Sep 30, 2026
UBS12,1830.07%US$13,036Sep 30, 2026
Fifth Third Bancorp10,0000.06%US$10,700Sep 30, 2026
Tower Research Capital LLC (TRC)2,4570.01%US$2,629Sep 30, 2026
Citigroup Inc534<0.01%US$571Sep 30, 2026
Wells Fargo232<0.01%US$248Sep 30, 2026
Signaturefd, LLC228<0.01%US$244Sep 30, 2026
SBI Securities Co., Ltd.202<0.01%US$216Sep 30, 2026
Group One Trading LLC178<0.01%US$190Sep 30, 2026
Hilltop National Bank73<0.01%US$78Sep 30, 2026
Fidelity60<0.01%US$64Sep 30, 2026
Jacobi Capital Management LLC40<0.01%US$43Sep 30, 2026
BNP Paribas23<0.01%US$25Sep 30, 2026
JPMorgan23<0.01%US$25Sep 30, 2026
Caitong International Asset Management Co., Ltd10<0.01%US$11Sep 30, 2026
Morgan Stanley2<0.01%US$2Sep 30, 2026
Dunhill Financial, LLC1<0.01%US$56Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund298K1.8%US$438KJun 30, 2026
Vanguard Extended Market Index Fund128K0.77%US$188KJun 30, 2026
Fidelity Extended Market Index Fund88,0240.53%US$138KMay 31, 2026
Fidelity Series Total Market Index Fund19,3880.12%US$30,439May 31, 2026
Fidelity Total Market Index Fund12,8110.08%US$20,113May 31, 2026
Fidelity Nasdaq Composite Index Fund5,2720.03%US$8,277May 31, 2026

Big stakes

StakeStakeSharesDateFiling
Blue Owl Capital Holdings LP9.99%1.13MMar 31, 2025Schedule 13G
New Enterprise Associates 16, L.P.9.90%1.67MNov 13, 2025Schedule 13D
Alyeska Investment Group, L.P.9.90%1.28MSep 30, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Joshua N. Silverman
Other companies: Femasys Inc. (Director · Since at least Nov 21, 2023); PharmaCyte Biotech, Inc. (Interim Chief Executive Officer, President, and Director · Since at least Aug 15, 2022); TAO Synergies Inc. (Executive Chairman · Since at least Jun 4, 2021); Petros Pharmaceuticals Inc (Vice-Chairman of the Board · Since at least Dec 1, 2020); Q/C Technologies, Inc. (Executive Chairman · Since at least Sep 6, 2018); Fabric.AI, Inc. (Chief Executive Officer, Director · Since at least Aug 15, 2016); Neurotrope Inc (Director · Aug 4, 2016 – Dec 1, 2020 · Past); Protagenic Therapeutics, Inc. (Director · Feb 12, 2016 – Feb 21, 2020 · Past); MGT Capital Investments, Inc. (Director · Dec 31, 2015 – Dec 31, 2015 · Past); National Holdings Corporation (Director · Jul 28, 2014 – Sep 12, 2016 · Past)
Director · Nov 28, 2016 – Oct 16, 2018 · Past
Steven A. Elms
Other companies: Elevation Oncology Inc (Director · Since at least Jun 17, 2022); ADMA Biologics Inc (Chairman · Since at least Feb 13, 2012); Zosano Pharma Corp (Director · May 17, 2018 – Jun 10, 2021 · Past); T2 Biosystems, Inc. (Director · Dec 9, 2015 – Dec 9, 2015 · Past); Cidara Therapeutics Inc (Director · Apr 14, 2015 – Apr 20, 2015 · Past); Loxo Oncology Inc (Director · Jul 31, 2014 – Feb 15, 2019 · Past); Ambit Biosciences Corp (Director · May 15, 2013 – Sep 2, 2014 · Past); Pernix Therapeutics Holdings Inc (Director · Aug 31, 2011 – May 26, 2016 · Past)
Director · Since at least Aug 6, 2019
Frederick G. Wasserman
Other companies: DLH Holdings Corp. (Chairman of the Board of Directors · Since at least Oct 3, 2007); National Holdings Corporation (Director · Sep 12, 2016 – Sep 12, 2016 · Past); SMTC Corporation (Director · Feb 4, 2015 – Apr 5, 2021 · Past); Gilman Ciocia Inc (Director · Oct 3, 2008 – Oct 15, 2013 · Past); Breeze-Eastern Corp (Director · Sep 13, 2007 – Jan 4, 2016 · Past); Crown Crafts, Inc. (Director · Aug 29, 2007 – Aug 12, 2009 · Past); MAM Software Group Inc (Director · Jul 17, 2007 – Oct 21, 2019 · Past)
Director · Jan 26, 2016 – Jun 8, 2021 · Past
Paul Edward Walker
Other companies: NeueHealth Inc (Director · Since at least Oct 2, 2025); Trillium Therapeutics Inc (Director · Jan 1, 2021 – Nov 17, 2021 · Past); Regulus Therapeutics Inc (Director · May 7, 2019 – May 7, 2019 · Past); Trevi Therapeutics, Inc. (Director · May 7, 2019 – May 7, 2019 · Past); Allakos Inc (Director · Jul 18, 2018 – May 15, 2025 · Past); Tesaro Inc (Director · Jun 27, 2012 – Jun 2, 2014 · Past)
Director · Oct 17, 2018 – Oct 17, 2018 · Past
John N Bonfiglio
Other companies: Qrons Inc (Chief Operating Officer · Jul 1, 2019 – Jul 1, 2019 · Past); Genprex, Inc. (Director · Feb 12, 2019 – Feb 12, 2019 · Past); Oragenics Inc. (President and CEO, Director · May 25, 2011 – Aug 13, 2014 · Past); Harrow, Inc. (President and CEO, Director · Oct 20, 2010 – Oct 20, 2010 · Past)
President and COO, Director · Jul 23, 2015 – Mar 9, 2017 · Past
Katharine Knobil
Other companies: Korro Bio, Inc. (Director · Since at least Aug 26, 2024); Pliant Therapeutics, Inc. (Director · Since at least Sep 14, 2022); Arena Pharmaceuticals Inc (Director · Jun 12, 2020 – Mar 11, 2022 · Past); Kaleido Biosciences, Inc. (Chief Medical Officer · Feb 27, 2019 – Oct 15, 2020 · Past)
Chief Medical Officer, Altesa BioSciences, Inc. · Since at least Dec 8, 2021
Eliot M Lurier
Other companies: Mustang Bio, Inc. (Interim CFO · Apr 18, 2022 – Apr 18, 2022 · Past); Tenax Therapeutics, Inc. (Interim CFO · Oct 29, 2021 – Oct 29, 2021 · Past); Interleukin Genetics Inc (Chief Financial Officer · Mar 23, 2011 – Oct 22, 2013 · Past)
Interim CFO · Jun 30, 2023 – Jun 30, 2023 · Past
Glynn Wilson
Other companies: Caring Brands, Inc. (Chief Executive Officer, Director · Since at least Oct 30, 2025); Cadrenal Therapeutics, Inc. (Board Member · Since at least Jan 19, 2023); Bonk, Inc. (Former CSO, Chairman, Director · Oct 30, 2020 – Mar 1, 2024 · Past)
Director · Jun 8, 2007 – Oct 9, 2018 · Past
Sherry Grisewood
Other companies: PetVivo Holdings Inc (Director · Aug 20, 2018 – Jan 15, 2019 · Past); Oncolix Inc (Director · Jun 26, 2018 – Jun 26, 2018 · Past)
Director · Nov 12, 2015 – Oct 16, 2018 · Past
Ann M Leen
Other companies: Kalaris Therapeutics, Inc. (Chief Scientific Officer · Jul 29, 2020 – Aug 16, 2022 · Past)
Chief Scientific Officer · Dec 21, 2018 – Feb 15, 2020 · Past
All 33 people
PersonSeat
Denis Corin
Other companies: Q BioMed Inc (Chief Executive Officer, Director · Apr 21, 2015 – May 26, 2022 · Past)
President, Director · Jun 8, 2007 – Feb 17, 2012 · Past
John Robert Wilson
Other companies: Kalaris Therapeutics, Inc. (Director · Jul 29, 2020 – May 25, 2021 · Past)
Director · Oct 17, 2018 – Jun 6, 2023 · Past
Juan F. Vera
Other companies: Kalaris Therapeutics, Inc. (Director · Jul 29, 2020 – Jun 6, 2024 · Past)
Chief Executive Officer & Co-Founder, Marker Therapeutics · Since at least Oct 17, 2018
Kathryn Penkus Corzo
Other companies: Matinas BioPharma Holdings, Inc. (Director · Nov 1, 2021 – Nov 1, 2023 · Past)
President and Chief Operating Officer, bit.bio · Since at least Oct 31, 2025
Ken Moseley
Other companies: Bellicum Pharmaceuticals Inc (Sr. VP and General Counsel · Dec 17, 2014 – Jan 3, 2018 · Past)
General Counsel · Dec 21, 2018 – Dec 21, 2018 · Past
Norman David Eansor
Other companies: Bio-Techne Corp (President-Protein Sciences · Jun 12, 2019 – Nov 12, 2021 · Past)
Director · Since at least May 9, 2019
Anna SzymanskaVice President, Quality · Mar 10, 2020 – Feb 27, 2023 · Past
Anthony H KimChief Financial Officer · Nov 27, 2018 – Mar 24, 2022 · Past
David EansorDirector · Since at least Nov 5, 2026
Edmund CheungVice President, Human Resources · Since at least Nov 4, 2026
Gerald GarrettVice President, Clinical Ops. · Mar 10, 2020 – Feb 17, 2022 · Past
Lynn DePippoDirector · Sep 7, 2010 – Sep 7, 2010 · Past
Mark ReddishDirector · Feb 17, 2012 – Oct 16, 2018 · Past
Mary NewmanHead of Regulatory Affairs · Since at least Nov 5, 2026
Michael LoiaconoChief Accounting Officer · Aug 25, 2016 – Feb 27, 2023 · Past
Mythili KoneruChief Medical Officer · May 9, 2019 – Feb 27, 2023 · Past
Nadia AgopyanSVP, Regulatory Affairs · Aug 15, 2019 – Feb 27, 2023 · Past
Patricia AllisonHead of Clinical Operations · Since at least Nov 4, 2026
Patrick A McGowanSecretary, Treasurer & CFO, Director · Jun 8, 2007 – Jun 8, 2007 · Past
Peter L HoangPresident and CEO, Director · Aug 14, 2019 – Mar 24, 2022 · Past
Steve ElmsManaging Partner, Aisling Capital · Since at least Nov 4, 2026
Tracy A MooreChief Financial Officer, Director · Aug 24, 2009 – Oct 14, 2009 · Past
Tsvetelina P HoangVP, Research and Development · Dec 21, 2018 – Feb 27, 2023 · Past

Open People

Log in to ask 6ix AI your own questions about Marker Therapeutics, Inc.